Calamos Advisors LLC Makes New $2.82 Million Investment in Tarsus Pharmaceuticals, Inc. $TARS

Key Points

• Calamos Advisors LLC initiated a new position in Tarsus Pharmaceuticals, buying 34,442 shares valued at about $2.82 million and owning roughly 0.08% of the company at quarter-end.
• Insider selling has been notable: two insiders sold 8,405 shares on March 19 at $67 each, and insiders have sold 79,391 shares (~$5.43 million) in the past 90 days, with insiders now holding 8.97% of the stock.
• Analysts are mixed but generally positive: the stock carries an average rating of “Moderate Buy” with an average price target of $90.67, while recent notes range from Zacks cutting to a hold to Oppenheimer initiating coverage at “outperform” with a $98 target.

Calamos Advisors LLC purchased a new position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 34,442 shares of the company's stock, valued at approximately $2,820,000. Calamos Advisors LLC owned approximately 0.08% of Tarsus Pharmaceuticals at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Osaic Holdings Inc. raised its position in shares of Tarsus Pharmaceuticals by 779.1% during the 2nd quarter. Osaic Holdings Inc. now owns 2,778 shares of the company's stock worth $113,000 after buying an additional 2,462 shares in the last quarter. Tower Research Capital LLC TRC raised its position in shares of Tarsus Pharmaceuticals by 220.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,045 shares of the company's stock worth $164,000 after buying an additional 2,782 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Tarsus Pharmaceuticals by 26.4% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,063 shares of the company's stock worth $169,000 after buying an additional 431 shares in the last quarter. West Wealth Group LLC bought a new stake in shares of Tarsus Pharmaceuticals during the 3rd quarter worth about $202,000. Finally, Valeo Financial Advisors LLC bought a new stake in shares of Tarsus Pharmaceuticals during the 3rd quarter worth about $209,000. 90.01% of the stock is currently owned by institutional investors.

Insider Activity

In other news, General Counsel Bryan Wahl sold 4,231 shares of Tarsus Pharmaceuticals stock in a transaction that occurred on Thursday, March 19th. The shares were sold at an average price of $67.00, for a total value of $283,477.00. Following the transaction, the general counsel directly owned 63,959 shares of the company's stock, valued at $4,285,253. This trade represents a 6.20% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Dianne C. Whitfield sold 4,174 shares of Tarsus Pharmaceuticals stock in a transaction that occurred on Thursday, March 19th. The stock was sold at an average price of $67.00, for a total transaction of $279,658.00. Following the completion of the transaction, the insider directly owned 35,028 shares in the company, valued at approximately $2,346,876. This trade represents a 10.65% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 79,391 shares of company stock valued at $5,432,035. 8.97% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the stock. Zacks Research cut shares of Tarsus Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, February 25th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Tarsus Pharmaceuticals in a research note on Tuesday, April 21st. Guggenheim lifted their price objective on shares of Tarsus Pharmaceuticals from $87.00 to $90.00 and gave the stock a "buy" rating in a research note on Wednesday, February 25th. Lifesci Capital raised shares of Tarsus Pharmaceuticals to a "strong-buy" rating in a research note on Monday, March 16th. Finally, Oppenheimer assumed coverage on shares of Tarsus Pharmaceuticals in a research note on Friday. They issued an "outperform" rating and a $98.00 price objective on the stock. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $90.67.

Tarsus Pharmaceuticals Stock Performance

Tarsus Pharmaceuticals stock opened at $61.45 on Monday. The firm's 50 day simple moving average is $69.17 and its 200-day simple moving average is $72.31. The company has a market cap of $2.62 billion, a P/E ratio of -37.93 and a beta of 0.63. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.85 and a quick ratio of 3.82. Tarsus Pharmaceuticals, Inc. has a fifty-two week low of $38.51 and a fifty-two week high of $85.25.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last released its earnings results on Monday, February 23rd. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.01). The firm had revenue of $151.67 million during the quarter, compared to analysts' expectations of $144.56 million. Tarsus Pharmaceuticals had a negative return on equity of 19.63% and a negative net margin of 14.72%. As a group, equities research analysts predict that Tarsus Pharmaceuticals, Inc. will post -0.72 EPS for the current year.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company's research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus's lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.